24 active not recruiting. 24 Phase 2, 4 Phase 1, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 24 | Active not recruiting 24 |
| Phase 1 | 4 | Active not recruiting 4 |
| Phase 3 | 4 | Active not recruiting 4 |
Follow Demyelinating Diseases: new trials by email Literature Review of Demyelinating Diseases trials Research Report on Demyelinating Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS) Ocrelizumab Test Formulation, Ocrelizumab Reference Formulation - Multiple Sclerosis | Phase 2 | Active not recruiting | Hoffmann-La Roche | 193 | 2025-11-13 | 2026-10-15 |
| Eculizumab For the Acute Attack of Neuromyelitis Optica Spectrum Disorder Intravenous Methylprednisolone (IVMP), Complement protein C5 inhibitor - Neuromyelitis Optica Spectrum Disorder Attack | Phase 2 | Active not recruiting | Tianjin Medical University General Hospital | 110 | 2025-09-09 | 2026-06-03 |
| "HB-adMSCs for the Treatment of Patients With Multiple Sclerosis" Autologous HB-adMSCs - Relapsing Remitting Multiple Sclerosis (RRMS), Multiple Sclerosis | Phase 2 | Active not recruiting | Hope Biosciences Research Foundation | 10 | 2025-05-02 | 2025-11-20 |
| An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis rapcabtagene autoleucel (YTB323) - Relapsing Multiple Sclerosis | Phase 1 / Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 28 | 2025-02-24 | 2026-09-02 |
| Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS) rapcabtagene autoleucel (YTB323) - Progressive Multiple Sclerosis | Phase 1 / Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 28 | 2024-12-12 | 2026-09-04 |
| KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis KYV-101, Standard lymphodepletion regimen, Anti-CD20 mAB - Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive | Phase 2 | Active not recruiting | Kyverna Therapeutics | 120 | 2024-09-20 | 2025-01-13 |
| A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone) Obexelimab, Placebo - Relapsing Multiple Sclerosis | Phase 2 | Active not recruiting | Zenas BioPharma (USA), LLC | 93 | 2024-08-26 | 2025-11-17 |
| Efficacy of Cognitive Behavioral Therapy for Insomnia to Treat Insomnia Symptoms in Individuals With Multiple Sclerosis Cognitive behavioral therapy for insomnia, Sleep and lifestyle education - Multiple Sclerosis, Insomnia | Phase 2 | Active not recruiting | University of Kansas Medical Center | 70 | 2024-07-30 | 2026-10-08 |
| Metformin Add-on Clinical Study in Multiple Sclerosis to Evaluate Brain Remyelination And Neurodegeneration Metformin Hydrochloride 850 mg Oral Tablet, Placebo - Multiple Sclerosis, Primary Progressive Multiple Sclerosis | Phase 2 | Active not recruiting | University Hospital, Antwerp | 120 | 2023-11-23 | 2025-06-24 |
| A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients Foralumab, Placebo - Secondary Progressive Multiple Sclerosis | Phase 2 | Active not recruiting | Tiziana Life Sciences LTD | 54 | 2023-11-15 | 2026-07-02 |
| Gene Transfer Clinical Trial for Infantile and Late Infantile Krabbe Disease Treated Previously With HSCT FBX-101 - Krabbe Disease | Phase 1 / Phase 2 | Active not recruiting | Duke University | 9 | 2023-02-03 | 2026-11-04 |
| Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders Daratumumab, Placebo - Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder | Phase 2 / Phase 3 | Active not recruiting | Tianjin Medical University General Hospital | 135 | 2022-11-01 | 2025-03-30 |
| Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD Ravulizumab - Neuromyelitis Optica Spectrum Disorder | Phase 2 / Phase 3 | Active not recruiting | Alexion Pharmaceuticals, Inc. | 12 | 2022-06-23 | 2026-06-24 |
| Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis N-acetyl cysteine, Placebo - Multiple Sclerosis, Multiple Sclerosis, Primary Progressive | Phase 2 | Active not recruiting | Emmanuelle Waubant, MD PhD | 98 | 2022-02-16 | 2026-03-11 |
| Study of Mesenchymal Autologous Stem Cells as Regenerative Treatment for Multiple Sclerosis MSCs, Saline - Multiple Sclerosis, Progressive Multiple Sclerosis | Phase 1 / Phase 2 | Active not recruiting | Haukeland University Hospital | 18 | 2021-08-09 | 2026-03-12 |
| ChariotMS - Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis Cladribine (MAVENCLAD®), Placebo - Advanced Multiple Sclerosis, Progressive Multiple Sclerosis | Phase 2 / Phase 3 | Active not recruiting | Queen Mary University of London | 204 | 2021-06-25 | 2026-09-08 |
| Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis SAR441344 IV, placebo IV, SAR441344 SC - Multiple Sclerosis | Phase 2 | Active not recruiting | Sanofi | 129 | 2021-06-07 | 2026-09-28 |
| A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) Efgartigimod PH20 SC - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Phase 2 | Active not recruiting | argenx | 229 | 2020-09-18 | 2026-11-04 |
| Dendritic Cells Therapy Combined With Immunomodulatory Treatment in Multiple Sclerosis Autologous peripheral blood differentiated adult tolerogenic dendritic cells expanded, Placebo - Relapsing-Remitting Multiple Sclerosis | Phase 2 | Active not recruiting | Judit Pich | 45 | 2020-01-27 | 2026-02-19 |
| A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis Ocrelizumab - Multiple Sclerosis | Phase 2 | Active not recruiting | Hoffmann-La Roche | 23 | 2020-01-09 | 2026-09-14 |
Showing 20 of 24. Sign in to see all of them.
Multiple Sclerosis (15) · Multiple Sclerosis, Chronic Progressive (7) · Neuromyelitis Optica (4) · Multiple Sclerosis, Relapsing-Remitting (3) · Autoimmune Diseases (2) · Autoimmune Diseases of the Nervous System (2) · Leukodystrophy, Globoid Cell (2) · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (2) · Sphingolipidoses (2) · Alpha-Methylacyl-CoA Racemase Deficiency (1) · Aspartylglucosaminuria (1) · Brain Diseases (1) · Brain Diseases, Metabolic (1) · Brain Diseases, Metabolic, Inborn (1) · Central Nervous System Diseases (1)
Nervous System Diseases (23) · Immune System Diseases (22) · Autoimmune Diseases (20) · Autoimmune Diseases of the Nervous System (20) · Demyelinating Autoimmune Diseases, CNS (20) · Chronic Disease (9) · Disease Attributes (9) · Pathological Conditions, Signs and Symptoms (9) · Pathologic Processes (8) · Cranial Nerve Diseases (4) · Eye Diseases (4) · Myelitis, Transverse (4) · Optic Nerve Diseases (4) · Optic Neuritis (4)
Tablets (2) · Acetylcysteine (1) · Antilymphocyte Serum (1) · Carmustine (1) · Cladribine (1) · Cognitive Behavioral Therapy (1) · Cytarabine (1) · Etoposide (1) · Melphalan (1) · Metformin (1) · Peripheral Blood Stem Cell Transplantation (1) · Prednisone (1) · Regimen B (1) · SLI381 (1) · Sleep (1)
Hoffmann-La Roche (2) · Novartis Pharmaceuticals (2) · Tianjin Medical University General Hospital (2) · Alexion Pharmaceuticals, Inc. (1) · Duke University (1) · Emmanuelle Waubant, MD PhD (1) · Fred Hutchinson Cancer Center (1) · Haukeland University Hospital (1) · Hope Biosciences Research Foundation (1) · Immunic AG (1) · Judit Pich (1) · Kyverna Therapeutics (1) · Masonic Cancer Center, University of Minnesota (1) · Queen Mary University of London (1) · Sanofi (1)
United States (14) · Spain (8) · Italy (7) · France (6) · Germany (5) · Poland (5) · Canada (4) · China (4) · Belgium (3) · Bulgaria (3) · Czechia (3) · Ukraine (3) · United Kingdom (3) · Australia (2) · Austria (2)
Andreas Muehler (1) · Barbara Willekens, MD, PhD (1) · Christopher Elnan Kvistad, PhD (1) · Djamchid Lotfi, MD (1) · Joanne Kurtzberg, MD (1) · Leona Holmberg (1) · Paul Orchard, M.D. (1) · Yolanda Blanco, MD (1)
PMID 35698927, PMID 36182028, PMID 36196048, PMID 38354138, PMID 38662979, PMID 39499628, PMID 39812825, PMID 41626064, PMID 42081777
2018 (2), 2016 (1), 2019 (1), 2023 (1)